Recent Advances in Progresses and Prospects of IL-37 in Central Nervous System Diseases.

作者信息

Li Xinrui, Yan Bing, Du Jin, Xu Shanshan, Liu Lu, Pan Caifei, Kang Xianhui, Zhu Shengmei

机构信息

Department of Anesthesiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.

Department of Anesthesiology, Haining People's Hospital, Haining 314499, China.

出版信息

Brain Sci. 2022 May 31;12(6):723. doi: 10.3390/brainsci12060723.

Abstract

Interleukin-37 (IL-37) is an effective anti-inflammatory factor and acts through intracellular and extracellular pathways, inhibiting the effects of other inflammatory cytokines, such as IL-1β, IL-6, and tumor necrosis factor-α (TNF-α), thereby exerting powerful anti-inflammatory effects. In numerous recent studies, the anti-inflammatory effects of IL-37 have been described in many autoimmune diseases, colitis, and tumors. However, the current research on IL-37 in the field of the central nervous system (CNS) is not only less, but mainly for clinical research and little discussion of the mechanism. In this review, the role of IL-37 and its associated inflammatory factors in common CNS diseases are summarized, and their therapeutic potential in CNS diseases identified.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e370/9221119/4d303863e324/brainsci-12-00723-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索